Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.04 USD | +2.27% | +2.03% | -18.41% |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
Sales 2024 * | 27.6B 2,202B | Sales 2025 * | 28B 2,234B | Capitalization | 80.46B 6,420B |
---|---|---|---|---|---|
Net income 2024 * | 403M 32.16B | Net income 2025 * | 6.35B 507B | EV / Sales 2024 * | 3.57 x |
Net Debt 2024 * | 18.15B 1,448B | Net Debt 2025 * | 12.68B 1,012B | EV / Sales 2025 * | 3.33 x |
P/E ratio 2024 * |
183
x | P/E ratio 2025 * |
12.4
x | Employees | 18,000 |
Yield 2024 * |
4.79% | Yield 2025 * |
5.04% | Free-Float | 99.92% |
Latest transcript on Gilead Sciences, Inc.
1 day | +2.26% | ||
1 week | +2.03% | ||
Current month | +1.37% | ||
1 month | -2.97% | ||
3 months | -11.22% | ||
6 months | -12.94% | ||
Current year | -18.41% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 28/02/19 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 31/12/15 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 11/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 16/10/20 |
Director/Board Member | 71 | 31/12/17 | |
Ted Love
BRD | Director/Board Member | 65 | 01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.99% | 0 M€ | +12.45% | - | |
8.10% | 0 M€ | 0.00% | - | |
8.06% | 0 M€ | 0.00% | - | |
5.23% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
10/05/24 | 66.13 | +2.40% | 5 165 756 |
09/05/24 | 64.58 | -0.52% | 6,048,572 |
08/05/24 | 64.92 | -0.82% | 5,134,980 |
07/05/24 | 65.46 | -0.12% | 7,318,161 |
06/05/24 | 65.54 | +1.17% | 7,187,265 |
Delayed Quote Nasdaq, May 10, 2024 at 06:22 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.41% | 80.53B | |
+31.08% | 695B | |
+26.51% | 568B | |
-4.62% | 361B | |
+19.71% | 330B | |
+3.92% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.75% | 168B |
- Stock Market
- Equities
- GILD Stock